Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort

Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort

<h4>Background</h4> <p>Psoriatic arthritis (PsA) recommendations state that the target of treatment should be remission or Low disease activity (LDA). We used a real life dataset to compare different potential targets.</p> <h4>Methods</h4> <p>250 PsA patien...

Descripció completa

Dades bibliogràfiques
Autors principals:	van Mens, L, van de Sande, M, van Kuijk, A, Baeten, D, Coates, L
Format:	Journal article
Idioma:	English
Publicat:	BMJ Publishing Group 2017

Ítems similars

Considerations for the definition of remission criteria in psoriatic arthritis
per: Mease, P, et al.
Publicat: (2017)

Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice
per: Leonieke J. J. van Mens, et al.
Publicat: (2017-10-01)

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
per: Henriëtte M. Y. de Jong, et al.
Publicat: (2019-09-01)

Treat to target in PsA should focus on clinical measures. Response to: ‘DAPSA versus cDAPSA: do we need use CRP?’ by Gonçalves et al.
per: Van Mens, L, et al.
Publicat: (2019)

Remission in psoriatic arthritis—where are we now?
per: Coates, L, et al.
Publicat: (2017)

Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al.
per: van Mens, L, et al.
Publicat: (2018)

Sustained very low disease activity and remission in psoriatic arthritis patients
per: Lubrano, E, et al.
Publicat: (2019)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
per: Coates, L, et al.
Publicat: (2018)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
per: Ennio Lubrano, et al.
Publicat: (2019-08-01)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
per: Coates, LC, et al.
Publicat: (2018)

Comparing the patient reported physical function outcome measures in a real‐life international cohort of patients with psoriatic arthritis
per: Leung, YY, et al.
Publicat: (2021)

Novel concepts in psoriatic arthritis management: Can we treat to target?
per: Tucker, L, et al.
Publicat: (2018)

The road to personalised medicine in psoriatic arthritis
per: White, JPE, et al.
Publicat: (2021)

Using etanercept to maintain remission of psoriatic arthritis during pregnancy
per: Ibrahim A Al-Homood, et al.
Publicat: (2014-01-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
per: Coates, L, et al.
Publicat: (2018)

What should be the primary target of "treat to target" in psoriatic arthritis?
per: Coates, LC, et al.
Publicat: (2018)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design
per: Rombach, I, et al.
Publicat: (2021)

Methotrexate in psoriasis and psoriatic arthritis
per: Coates, L, et al.
Publicat: (2020)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
per: Coates, L, et al.
Publicat: (2022)

Psoriatic arthritis: prospects for the future
per: Hackett, S, et al.
Publicat: (2022)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis
per: Coates, L, et al.
Publicat: (2017)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
per: Coates, L, et al.
Publicat: (2017)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
per: Coates, L, et al.
Publicat: (2018)

Identification of psoriatic arthritis in patients with psoriasis
per: Coates, LC, et al.
Publicat: (2023)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Psoriatic arthritis
per: FitzGerald, O, et al.
Publicat: (2021)

Current concepts and unmet needs in psoriatic arthritis
per: Mahmood, F, et al.
Publicat: (2017)

Psoriatic arthritis: prospects for the future
per: Simon Hackett, et al.
Publicat: (2022-03-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
per: Coates, L, et al.
Publicat: (2016)

Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo.
per: Arno W R van Kuijk, et al.
Publicat: (2010-01-01)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
per: L. C. Coates, et al.
Publicat: (2018-12-01)

Psoriatic arthritis: An up to date overview
per: Simon Hackett, et al.
Publicat: (2020-01-01)

Personalized medicine - a new reality in psoriatic arthritis?
per: Al-Mossawi, H, et al.
Publicat: (2018)

The impact of psoriatic arthritis on quality of life: a systematic review
per: James, L, et al.
Publicat: (2024)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
per: Coates, L, et al.
Publicat: (2020)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
per: Ananaya Datta-Mitra, et al.
Publicat: (2014-01-01)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design
per: Ines Rombach, et al.
Publicat: (2021-03-01)

Outcome measures in psoriatic arthritis: where next?
per: Hackett, S, et al.
Publicat: (2022)

Should methotrexate have any place in the treatment of psoriatic arthritis?
per: Ye, W, et al.
Publicat: (2019)

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
per: Poddubnyy, D, et al.
Publicat: (2021)